Tuhura Biosciences Stock Performance
| HURA Stock | 4.92 0.13 2.57% |
On a scale of 0 to 100, TuHURA Biosciences holds a performance score of 2. The entity has a beta of -1.96, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning TuHURA Biosciences are expected to decrease by larger amounts. On the other hand, during market turmoil, TuHURA Biosciences is expected to outperform it. Please check TuHURA Biosciences' jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether TuHURA Biosciences' existing price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in TuHURA Biosciences are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, TuHURA Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.57) | Five Day Return 5.58 | Year To Date Return 19.71 | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:35 | Last Split Date 2024-10-18 |
1 | Agios Pharm earnings beat by 1.00, revenue fell short of estimates | 10/31/2024 |
2 | Acquisition by Dearborn Dan of 489848 shares of TuHURA Biosciences at 4.94 subject to Rule 16b-3 | 11/12/2024 |
3 | TuHURA Biosciences Announces Executive Salary and Stock Options - TipRanks | 11/15/2024 |
4 | Hanmi Pharm. Co., Ltd. Stock Has Shown Weakness Lately But Financials Look Strong Should Prospective Shareholders Make The Leap | 12/10/2024 |
5 | HURA Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders | 12/12/2024 |
6 | TuHURA Biosciences Now Covered by Rodman Renshaw | 12/20/2024 |
7 | PharmD Capital Launches Advanced Technical Analysis Course Online-A Raw, No-Nonsense Course to Gain an Edge in the Markets | 12/24/2024 |
8 | Acquisition by Ng George K of 51275 shares of TuHURA Biosciences at 4.11 subject to Rule 16b-3 | 01/02/2025 |
9 | Should Weakness in ST Pharm Co.,Ltd.s Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials | 01/03/2025 |
10 | Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer | 01/17/2025 |
| Begin Period Cash Flow | 14.3 M | |
| Free Cash Flow | -12 M |
TuHURA |
TuHURA Biosciences Relative Risk vs. Return Landscape
If you would invest 548.00 in TuHURA Biosciences on November 2, 2024 and sell it today you would lose (56.00) from holding TuHURA Biosciences or give up 10.22% of portfolio value over 90 days. TuHURA Biosciences is currently generating 0.3587% in daily expected returns and assumes 10.8402% risk (volatility on return distribution) over the 90 days horizon. In different words, 96% of stocks are less volatile than TuHURA, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TuHURA Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TuHURA Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TuHURA Biosciences, and traders can use it to determine the average amount a TuHURA Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0331
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HURA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.84 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.36 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average TuHURA Biosciences is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TuHURA Biosciences by adding it to a well-diversified portfolio.
TuHURA Biosciences Fundamentals Growth
TuHURA Stock prices reflect investors' perceptions of the future prospects and financial health of TuHURA Biosciences, and TuHURA Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TuHURA Stock performance.
| Current Valuation | 212.18 M | ||||
| Shares Outstanding | 26 M | ||||
| Price To Book | 146.92 X | ||||
| EBITDA | (29.12 M) | ||||
| Net Income | (29.32 M) | ||||
| Total Debt | 2.34 M | ||||
| Cash Flow From Operations | (7.18 M) | ||||
| Market Capitalization | 141.65 M | ||||
| Total Asset | 4.36 M | ||||
| Retained Earnings | (88.47 M) | ||||
| Working Capital | 562.42 K | ||||
About TuHURA Biosciences Performance
By analyzing TuHURA Biosciences' fundamental ratios, stakeholders can gain valuable insights into TuHURA Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if TuHURA Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if TuHURA Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (7.73) | (7.34) | |
| Return On Capital Employed | (44.72) | (42.48) | |
| Return On Assets | (7.73) | (7.34) | |
| Return On Equity | 16.93 | 17.77 |
Things to note about TuHURA Biosciences performance evaluation
Checking the ongoing alerts about TuHURA Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TuHURA Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TuHURA Biosciences had very high historical volatility over the last 90 days | |
| TuHURA Biosciences has a very high chance of going through financial distress in the upcoming years | |
| TuHURA Biosciences was previously known as KTRA Old and was traded on NASDAQ Exchange under the symbol KTRA. | |
| Net Loss for the year was (29.32 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| TuHURA Biosciences generates negative cash flow from operations | |
| TuHURA Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer |
- Analyzing TuHURA Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TuHURA Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining TuHURA Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TuHURA Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TuHURA Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TuHURA Biosciences' stock. These opinions can provide insight into TuHURA Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for TuHURA Stock analysis
When running TuHURA Biosciences' price analysis, check to measure TuHURA Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TuHURA Biosciences is operating at the current time. Most of TuHURA Biosciences' value examination focuses on studying past and present price action to predict the probability of TuHURA Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TuHURA Biosciences' price. Additionally, you may evaluate how the addition of TuHURA Biosciences to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |